RudaCure, a company specializing in the development of treatments for 感觉障碍, announced on the 3rd that its 慢性疼痛治疗药 (RCI002) has been selected as a supported project by the 韩国药物开发基金 (KDDF), and that optimization research to derive a 先导化合物 will now begin in earnest.
RudaCure's RCI002 is a compound that selectively inhibits the activity of TRPV1, a key target known for developing powerful 非麻醉性镇痛药. According to the company's preliminary research, the compound demonstrated TRPV1 inhibitory activity and reduced pain in 慢性疼痛 动物模型. Unlike existing TRPV1 antagonists, it does not cause 异常发热, offering excellent 镇痛疗效 with no significant 副作用, giving it high potential for development as a safe treatment.
In particular, the company expects synergistic effects for the optimization research of RCI002 through joint execution of this support project with the team of Professor Park Cheol-gyu at 嘉泉大学医学院 — a specialist in 疼痛治疗药 development who is participating as the lead institution.
Source: BioTimes (http://www.biotimes.co.kr)